FLM-7523 / Flamingo Therapeutics - LARVOL DELTA

Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer (PRNewswire) - "Dr. Andrew Denker, Flamingo's Chief Medical Officer, will deliver an oral presentation on the Company's approach to developing RNA therapeutics against difficult-to-drug targets for cancer indications. Dr. Denker will discuss Flamingo's novel oligonucleotide targeting the long noncoding RNA (lncRNA) MALAT1, FLM-7523, discovered by Ionis Pharmaceuticals, which has recently completed IND-enabling preclinical activities and is moving toward a Phase 1 First-in-Human trial in solid tumors.."

Clinical • Preclinical • Oncology • Solid Tumor

Preclinical development of FTX-001: First-in-class inhibitor of the long non-coding RNA MALAT1 (EACR 2024) - "The No-Observed-Adverse-Effect Level was the top dose studied in both species. FTX-001 plasma PK tissue distribution and PPB results were consistent with that expected with ASOs in the tested species.Conclusion Taken together, these results demonstrate that FTX-001 has the potential to achieve target engagement (MALAT1 knockdown) in tumors at tolerated doses in cancer patients and has a preclinical benefit-risk profile supportive of advancement to Phase 1 human trials."

Preclinical • Breast Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MALAT1

Flamingo Therapeutics Announces Poster Presentation at EACR 2024 Congress on FLM-7523 (FTX-001), a First-in-Class Inhibitor of the Long Non-Coding RNA MALAT1 (PRNewswire) - "Flamingo Therapeutics...today announced a poster presentation on FLM-7523 (also referred to as FTX-001) at the Annual Congress of the European Association for Cancer Research (EACR) 2024 Congress, being held in Rotterdam, Netherlands from June 10-13, 2024. Flamingo will present preclinical results highlighting the candidate selection and characterization of FLM-7523, a novel oligonucleotide targeting MALAT1 for the treatment of cancer."

Preclinical • Oncology • Solid Tumor

Preclinical development of FTX-001: first in class inhibitor of the long non-coding RNA MALAT1 (AACR 2023) - "Ongoing histopathological evaluation will complete the health hazard evaluation of FTX-001. Taken together, these results demonstrate the high potency and good preclinical safety profile of FTX-001 which supports the potential to achieve good target engagement (MALAT1 RNA knock down in human tumors) at well tolerated clinical doses in cancer patients."

Preclinical • Breast Cancer • Oncology • Solid Tumor • MALAT1

Flamingo Therapeutics Announces Poster Presentation on FTX-001 at the 2023 American Association for Cancer Research (AACR) Annual Meeting (PRNewswire) - "Flamingo Therapeutics...announced a presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida. Flamingo will present preclinical results highlighting the candidate selection and characterization of FTX-001, a novel antisense oligonucleotide targeting MALAT1 for the treatment of cancer. Flamingo is currently advancing FTX-001 through Phase 1 enabling preclinical activities and is planning for a First-in-Human trial in solid tumors."

Preclinical • Oncology • Solid Tumor

Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology (PRNewswire) - "Flamingo Therapeutics ('Flamingo') and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company. The combined company will advance Flamingo's lead programs: danvatirsen in a Phase II trial PEMDA-HN in Head & Neck cancer (danvatirsen in combination with pembrolizumab) and other indications; and FTX-001 targeting MALAT-1 in cancer (IND ready). In addition, Flamingo's current investors Kurma Partners (France) and PMV (Belgium) made a further investment in the company....'We have tremendous confidence in danvatirsen and our MALAT-1 targeted ASO (FTX-001), and look forward to delivering on our ambitious clinical plan with multiple readouts planned for 2024 and 2025'."

M&A • Head and Neck Cancer • Oncology